Short Communication
Published: 26 October, 2018 | Volume 2 - Issue 1 | Pages: 075-081
Fluorescein was conjugated with 1-methyl-o-carborane and the resulting bioconjugate was biologically evaluated through microscopic and flow cytometric studies in pancreatic cancer and squamous cell carcinoma cell lines. The uniform distribution of this bioconjugate, as well as its moderate cytotoxicity and higher boron content relative to present boronated delivery agents sodium borocaptate (BSH) and boronophenylalanine (BPA), provide justification for its further evaluation as a potential delivery agent for BNCT.
Read Full Article HTML DOI: 10.29328/journal.aac.1001016 Cite this Article Read Full Article PDF
Boron neutron capture therapy; Carborane; Fluorescein; Bioconjugate; Theranostic
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."